GlaxoSmithKline celebrated its 50th anniversary of doing business in Singapore, by opening its new S$600 million vaccine plant. This facility is GSK’s first primary vaccine manufacturing plant and its biggest investment in Asia. The plant will be one of only two global sites to produce purified bulk polysaccharides and conjugates, which are used to manufacture GSK's new pneumococcal conjugate vaccine, meningitis, and other new innovative vaccines.

The opening of GSK’s vaccine plant also marks the beginning of GSK’s 10-year roadmap with the EDB to boost excellence in R&D, green manufacturing and talent development. In line with this roadmap, GSK will set up an Academic Centre of Excellence to further support drug discovery in Singapore. GSK also announced a S$30 million endowment fund to support graduate studies and research in green manufacturing and public health policy. EDB will contribute another S$20 million to this endowment fund to develop capabilities in manufacturing technologies of the future.

"We are delighted to celebrate 50 years of pioneering work in Singapore,” said Mr. Andrew Witty, CEO, GSK. “We look forward to growing our strategic partnership for the next 10 years and beyond and establishing Singapore as GSK’s home for business, innovation, and talent, as encapsulated in our new vaccine plant.”